Development of multimodal polymeric imaging agents for enhanced preclinical imaging of disease
|Dual-modal polymeric imaging agent that incorporates optical and F-19 MR for tumour detection in vivo.|
Nanomaterials, Nanobiotechnology, Health, Nanomedicine, Molecular imaging, Magnetic resonance imaging, Positron Emission Tomography, Fluorescence imaging, Nanotechnology, Polymer
Molecular imaging follows biological processes in living subjects by utilising one of a variety of available techniques. Molecular imaging agents can be designed for various functions: to diagnose and differentiate diseased tissue from normal tissue; to provide information on a disease state (prognosis); and ultimately to monitor the effect of a treatment. Multi-modal imaging agents provide unique opportunities to probe disease states in vivo. The development of polymeric molecular imaging agents that combine high resolution capabilities (for example, that afforded by magnetic resonance imaging (MRI) with other more sensitive techniques, leads to significant possibilities for increasing our understanding of biological processes in live animals. To fully utilise this capability, this project explores the development of advanced architectural polymers that facilitates probing of disease states using various complementary imaging modalities such as positron emission tomography (PET), magnetic resonance imaging (MRI), x-ray and computed tomography (CT) and optical imaging.
|Lead investigator||Dr Kristofer Thurecht
|Research group||Whittaker Group|